Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 10/20 | 0.51 |
| ▸ | LMNA | P02545 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14487951 | 1.00 | KMT2A (0.66) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL29369833 | 1.00 | KMT2A (0.66) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15847989 | 1.00 | KMT2A (0.66) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15848170 | 1.00 | KMT2A (0.66) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15847582 | 0.92 | POLB (0.64) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15847488 | 0.92 | POLB (0.64) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15847487 | 0.92 | POLB (0.64) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15848444 | 0.91 | KMT2A (0.66) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL15848442 | 0.91 | KMT2A (0.66) | KMT2AMAPTHTR2BPOLBTP53 | |
| SCHEMBL17457225 | 0.91 | MAPT (0.57) | KMT2AMAPTHTR2BPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260062486-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12522570-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667477-A2 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3974426-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114206319-A | Pharmaceutical composition for treating HBV | 组装生物科学股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220081433-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES INC (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3941921-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | Arbutus Biopharma Corporation (CA) | 2022-01-26 | — | — | EP | disclosed |
| EP-3349761-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | KMT2A 2849/4885MAPT 3599/4885HTR2B 1517/4885 |
| US-20260062486-A1 | ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B | PDCD1, CD274, PDCD4 | KMT2A 3675/4885MAPT 820/4885HTR2B 3933/4885 |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | KMT2A 3358/4885MAPT 3799/4885HTR2B 904/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | KMT2A 1216/4885MAPT 3763/4885HTR2B 3521/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | KMT2A 3876/4885MAPT 3090/4885HTR2B 1597/4885 |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | KMT2A 1157/4885MAPT 3557/4885HTR2B 4572/4885 |
| US-20220081433-A1 | CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, SMC1A | KMT2A 2920/4885MAPT 4435/4885HTR2B 3953/4885 |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | HAVCR2, PNP, ADAR | KMT2A 1704/4885MAPT 4353/4885HTR2B 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.